Helio AI | $1,000,000 | (Nov 27, 2025)
Procure Ai | $13,000,000 | (Nov 27, 2025)
Overstory | $43,000,000 | (Nov 27, 2025)
Certified by Founder
Lodge
Braveheart Bio
start up
United States
- San Francisco, California
- 06/11/2025
- Series A
- $185,000,000
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
- Industry Biotechnology Research
- Website https://www.braveheart.bio/
- LinkedIn https://www.linkedin.com/company/braveheart-bio/
Global Work AI | $2,400,000 | (Nov 27, 2025)
SubImage (YC W25) | $4,200,000 | (Nov 27, 2025)
AUGMENTT | $18,000,000 | (Nov 27, 2025)
EcoG | $18,573,280 | (Nov 27, 2025)
Parallax Worlds | $4,900,000 | (Nov 27, 2025)
CoPlane | $14,000,000 | (Nov 27, 2025)
The Intelligent Search Company (TISC) | $2,100,000 | (Nov 27, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)